Ronald Gust

Prof. Ronald Gust

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2012 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
WLWukun Liu
Wukun Liu
RGRonald Gust
Ronald Gust
The discovery of cisplatin's antitumor activity in 1969 prompted the search for novel metal-containing complexes as potential anticancer drugs. Among these novel complexes, metal N-heterocyclic carbene (NHC) complexes have recently gained considerable attention because they perfectly fit prerequisites for efficient drug design and fast optimization. Moreover, most of them have shown higher cytotoxicity than cisplatin. This review describes the advances that have been achieved in using transition metal (Ag, Au, Pt, Pd, Cu, Ni, and Ru) complexes containing NHC ligands as antitumor agents. Their modes of action at the cellular lever are further discussed. All these initial achievements clearly demonstrate the great potential of metal–NHC complexes as antitumor agents.

14 June 2022 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
YLYunlong Lu
Yunlong Lu
XMXiaoyan Ma
Xiaoyan Ma
XCXingyu Chang
Xingyu Chang
ZLZhenlin Liang
Zhenlin Liang
LLLin Lv
Lin Lv
Wukun LiuWukun Liu
Wukun Liu
Metal complexes have demonstrated significant antitumor activities and platinum complexes are well established in the clinical application of cancer chemotherapy. However, the platinum-based treatment of different types of cancers is massively hampered by severe side effects and resistance development. Consequently, the development of novel metal-based drugs with different mechanism of action and pharmaceutical profile attracts modern medicinal chemists to design and synthesize novel metal-based agents. Among non-platinum anticancer drugs, gold complexes have gained considerable attention due to their significant antiproliferative potency and efficacy. In most situations, the gold complexes exhibit anticancer activities by targeting thioredoxin reductase (TrxR) or other thiol-rich proteins and enzymes and trigger cell death via reactive oxygen species (ROS). Interestingly, gold complexes were recently reported to elicit biochemical hallmarks of immunogenic cell death (ICD) as an ICD inducer. In this review, the recent progress of gold(I) and gold(III) complexes is comprehensively summarized, and their activities and mechanism of action are documented.

4 April 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
WLWukun Liu
Wukun Liu
KBKerstin Bensdorf
Kerstin Bensdorf
MPMaria Proetto
Maria Proetto
AHAdelheid Hagenbach
Adelheid Hagenbach
UAUlrich Abram
Ulrich Abram
RGRonald Gust
Ronald Gust

21 October 2004 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RGRonald Gust
Ronald Gust
IOIngo Ott
Ingo Ott
DPDiana Posselt
Diana Posselt
KSKlaus Sommer
Klaus Sommer

1 March 2004 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
SFSabine Fuchs
Sabine Fuchs
TKTimo Kapp
Timo Kapp
HOHenning Otto
Henning Otto
TSTorsten Schöneberg
Torsten Schöneberg
PFPeter Franke
Peter Franke
ASA. Dieter Schlüter
A. Dieter Schlüter

4 March 2009 in JBIC Journal of Biological Inorganic Chemistry
Verified
Journal Article
Closed access
PDF file
AHAnnegret Hille
Annegret Hille
IOIngo Ott
Ingo Ott
AKAna Kitanovic
Ana Kitanovic
IKIgor Kitanovic
Igor Kitanovic
HAHamed Alborzinia
Hamed Alborzinia
RGRonald Gust
Ronald Gust